Pay in 4 interest-free payments of $6.61 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
GLP-1 RA-based therapies confer cardiovascular benefits and favourable metabolic effects, such as weight loss [8, 9], with emerging evidence of kidney protection [8,9,10,11,12,12]
Given the severity of VTE and the increasingly widespread use of GLP1RAs, 4 the public health impact of the excess risk of DVT deserves careful scrutiny and requires further investigation
doi: 10.1530/joe-18-0374 28 YamamotoCMiyoshiHOnoKSugawaraHKamedaRIchiyamaMet al
2018;6: e4774
Dual-action GIP/GLP-1 receptor agonist with strong clinical trial outcomes
Conclusions GLP-1 receptor agonists significantly reduce major cardiovascular events and mortality in high-risk populations, with a favourable long-term safety profile
US$ 24.45
US$ 28.88
US$ 28.04
US$ 28.51
US$ 24.12
US$ 20.25
US$ 26.57
US$ 27.97
